This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna (CI) Evernorth Business Ties Up With Kaiser Permanente
by Zacks Equity Research
Cigna (CI) arm Evernorth partners with integrated health care organization Kaiser Permanente to offer better care to Kaiser members.
MarketAxess (MKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
MarketAxess' (MKTX) Q1 earnings is likely to reflect decreased revenues, offset by solid trading volumes.
Why Cigna (CI) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Stocks to Watch for Following Recent Broker Upgrade
by Maharathi Basu
We believe, broker-friendly stocks like ArcBest (ARCB), Archer Daniels (ADM), ABM Industries (ABM), Caleres (CAL) and Cigna (CI) should be on an investor's watchlist.
Why You Should Retain Teladoc Health (TDOC) Stock for Now
by Zacks Equity Research
Teladoc Health (TDOC) is focused on making strategic partnerships to boost user numbers.
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Teladoc Health's (TDOC) Virtual Care Model to Aid Companies
by Zacks Equity Research
Teladoc Health's (TDOC) first industry-standard model to help employers improve their package of telehealth services.
Cigna Corp. (CI) Up 7.8% in 3 Months: More Room to Grow?
by Zacks Equity Research
Cigna Corp. (CI) expects to buy back more than $7 billion worth of shares in 2022.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Teladoc Health (TDOC) Tumbling: Is it Healthy for Your Portfolio?
by Zacks Equity Research
For this year, Teladoc Health (TDOC) projects total visits in the band of 18.5-20 million, indicating a rise from the 2021 level of 15.4 million.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Cigna (CI) Unveils '22 Capital Deployment Plans, Shares Up
by Zacks Equity Research
Cigna's (CI) shares gain on plans to deploy capital via share buybacks and targeted bolt-on acquisitions, which reflect its financial strength.
Teladoc Health (TDOC), Amazon Tie Up to Advance Virtual Care
by Zacks Equity Research
Teladoc Health (TDOC) collaborates with Amazon so that customers can avail quick and effective virtual care medical services via their Alexa-activated intelligent speakers.
Select Medical (SEM) Q4 Earnings Beat on Higher Admissions
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results reflect solid revenues driven by robust contributions from all its segments, partly offset by higher costs and expenses.
Cigna (CI) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Teladoc (TDOC) Unveils Solution to Ease Whole-Person Care
by Zacks Equity Research
Teladoc Health (TDOC) launches Chronic Care Complete for extending a comprehensive suite of chronic condition management services for serving the whole-person health needs of eligible members.
UnitedHealth Group (UNH) Bolsters Presence With Contract Win
by Zacks Equity Research
UnitedHealth Group's (UNH) unit UnitedHealthcare receives a contract from the District of Columbia aimed at improving health outcomes of District Dual Choice program enrollees in the district.
Humana (HUM) Okays Dividend Hike, Boosts Shareholder Value
by Zacks Equity Research
Humana's (HUM) recent dividend hike highlights its sound financial position and sincere efforts to reward shareholders.
EverQuote (EVER) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
EverQuote's (EVER) Q4 results reflect growth in the Variable Marketing Margin and a solid performance in the other insurance vertical.
Centene (CNC) Q4 Earnings Beat on Solid Membership Growth
by Zacks Equity Research
Centene's (CNC) fourth-quarter results indicate improved premium and service revenues coupled with sound membership growth. A solid 2022 guidance should impress investors.
Cigna (CI) Q4 Earnings Beat on Robust Cigna Healthcare Unit
by Zacks Equity Research
Cigna's (CI) fourth-quarter results benefit from strong medical customer growth. A solid outlook for 2022 when compared to the 2021 level remains noteworthy.
Cigna (CI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 1.92% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
MetLife (MET) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of 52.82% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cigna's (CI) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cigna's (CI) fourth-quarter earnings results likely to reflect higher revenues and solid segmental contributions.